Lianne Lin, MD
Pulmonary Disease · Portland, ORNPI 1497910210
Payments from drug & device makers
What this record shows
The money is spread across several categories — gifts (48.5%), food and beverage and education — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Resmed Corp at 48.5% of the total. Reporting peaked in 2019 at $669 and has fallen 81.8% since, to $122 in 2025.
Across 14 payments — averaging $75.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Resmed Corp$510
- Merck$139
- United Therapeutics Corporation$139
- Intuitive Surgical$135
- Boehringer Ingelheim$57
- GSK$28
- plus $43 from 2 others
Across 36 payments — averaging $2632.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$84K
- United Therapeutics Corporation$11K
What the payments were for
- Food & beverage$49647%
- Education$454%
- Gifts$51049%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Resmed Corp | 3 | $510 |
| Merck | 2 | $139 |
| United Therapeutics Corporation | 2 | $139 |
| Intuitive Surgical | 1 | $135 |
| Boehringer Ingelheim | 3 | $57 |
| GSK | 1 | $28 |
| Baxter Healthcare | 1 | $22 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AirCurve$270
- AirSense$240
- Da Vinci Surgical System$135
How this compares
$1,051 in reported general payments places this provider in the 60th percentile of 154 pulmonary disease providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 91 | $1,129,470 |
| Tyvaso DpiTreprostinil | 44 | $1,129,360 |
| AdempasRiociguat | 35 | $494,082 |
| Orenitram ErTreprostinil Diolamine | 55 | $353,253 |
| OfevNintedanib Esylate | 24 | $321,135 |
| UptraviSelexipag | 21 | $269,632 |
| WinrevairSotatercept-Csrk | 18 | $261,099 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 198 | $160,364 |
| Ambrisentan | 56 | $140,573 |
| Breo ElliptaFluticasone/Vilanterol | 179 | $80,775 |
| Tadalafil | 100 | $66,411 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 65 | $54,555 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 61 | $30,889 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 52 | $30,871 |
| Spiriva RespimatTiotropium Bromide | 38 | $26,359 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $20 | $1,399,102112 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $57 | $378,382123 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta | $28 | $290,193480 claims |
| MerckWinrevair, Dulera, Asmanex | $139 | $274,54765 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 154 pulmonary disease providers in Oregon.
Other pulmonary disease in Portland
- Stephen YauPortland$984K
- Matthew DrakePortland$135K
- Peter LeePortland$98K
- Jordan FeinPortland$87K
- Granthem FarrPortland$66K
- David HotchkinPortland$65K
- Jeffrey RobinsonPortland$51K
- Steven SearsPortland$21K
- Melvin MorganrothPortland$14K
- Christina MacrostyPortland$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.